Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study
Year: 2020
Type: article
Study design: Observational Study
Abstract: Due to a high efficacy in clinical trials, sofosbuvir (SOF) and ribavirin (RBV) for 12 or 16 weeks is recommended for treatment of patients with HCV genotype (GT) 2 infection. We investigated safety and effectiveness of these regimens for GT2 in HCV-TARGET participants.
DOI: 10.17615/v2jq-xc82
Authors: Fried, Michael W., Sulkowski, Mark S., Di Bisceglie, Adrian, Nelson, David R., Galati, Joseph S., Pockros, Paul, Welzel, Tania M., Frazier, Lynn M., Darling, Jama, Zeuzem, Stefan, Lim, Joseph K., Kuo, Alexander, Reddy, Rajender K., Vainorius, Monika, Alqahtani, Saleh, Akushevich, Lucy, Morelli, Giuseppe
Institution: University of North Carolina at Chapel Hill
Language: English
Topic: Hepatitis C virus research
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4297934695